Abstract
MPS1 kinase is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation. It has been found aberrantly overexpressed in a wide range of human tumors and is necessary for tumoral cell proliferation. Here we report the identification and characterization of NMS-P715, a selective and orally bioavailable MPS1 small-molecule inhibitor, which selectively reduces cancer cell proliferation, leaving normal cells almost unaffected. NMS-P715 accelerates mitosis and affects kinetochore components localization causing massive aneuploidy and cell death in a variety of tumoral cell lines and inhibits tumor growth in preclinical cancer models. Inhibiting the SAC could represent a promising new approach to selectively target cancer cells. ©2010 AACR.
Cite
CITATION STYLE
Colombo, R., Caldarelli, M., Mennecozzi, M., Giorgini, M. L., Sola, F., Cappella, P., … Moll, J. (2010). Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Research, 70(24), 10255–10264. https://doi.org/10.1158/0008-5472.CAN-10-2101
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.